A Percutaneous Ultrasound Device With Needle Guide for Vascular Access

NCT ID: NCT03879161

Last Updated: 2025-10-16

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: NA
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-09-30
• Study Completion Date: 2028-12-31

Brief Summary

This first-in-human pilot study seeks to evaluate the feasibility and safety of using a percutaneous ultrasound device with needle guide for vascular access. Eligible participants will undergo the procedure of transcatheter arterial chemoembolization for primary or metastatic liver cancer, as part of participants' clinical care. The percutaneous ultrasound device with needle guide will be deployed in eligible participants at the beginning of the procedure for guiding a needle inside the femoral artery. Once the needle is inside the artery, then a guide wire is advanced inside the needle and vascular access is successfully obtained.

The study will identify whether this ultrasound-based device with needle guide is helpful for guiding a needle inside the femoral artery.

Detailed Description

This NIH Small Business Innovation Research (SBIR)-funded study seeks to test a forward-viewing, ultrasound (US)-based device with needle guide for vascular access.

Access to large arteries is an indispensable step of any trans-arterial catheterization procedure. Surface US-guided vascular cannulation greatly improves first-pass success and reduces complications and is recommended as the preferred technique by numerous specialties and governmental agencies. Surface US-guided cannulation has several key limitations, including dependence on operator skills and experience. Safety and success of vascular access could be vastly improved with a single integrated imaging/interventional device with a small footprint that enables a single-hand operation of the US probe and visualizes the operating needle in real-time.

Reliable and accurate real-time image guidance for vascular access has the potential to appreciably impact public health by enhancing patient safety and convenience, improving procedural accuracy and increasing procedure throughput. Successful implementation has the potential to reduce care and complication costs across millions of vascular access procedures.

Vu-Path™ is a small footprint, US-based device with needle guide. It is a dual-lumen instrument with parallel US imaging and interventional lumens. The forward-viewing US transducer is located at the catheter tip and focused such that the tip of the needle in the interventional lumen, and all proximate structures, are always clearly visualized in real time throughout the procedure.

This is a first-in-human pilot study of the Vu-Path™ device, aiming to its establish clinical feasibility and safety for exemplary use.

Conditions

Vascular Access

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Device Arm

Study participants will be enrolled in the Device Arm and the Vu-Path™ Device will be used to access the femoral artery for intra-arterial chemoembolization.

Group Type: EXPERIMENTAL

Vu-Path™

Intervention Type: DEVICE

Femoral arterial access in eligible participants will be performed using the Vu-Path™.

Interventions

Vu-Path™

Femoral arterial access in eligible participants will be performed using the Vu-Path™.

Intervention Type: DEVICE

Other Intervention Names

Percutaneous Ultrasound Device With Needle Guide

Eligibility Criteria

Inclusion Criteria

• Male or female participants, 18 years of age or older at the time of enrollment.
• Participants meeting all medical conditions for percutaneous angiography.
• International Normalized Ratio (INR) <1.3.
• Written informed consent to participate in the study.
• Ability to comply with the requirements of the study procedures.

Exclusion Criteria

• Fibrous tissue in access path.
• Active skin infection at the point of needle insertion.
• Hemophilia, thrombocytopenia, coagulopathy, or other elevated risk for bleeding or abnormal clotting
• Use of antithrombotic medication.
• For participants taking warfarin or other anticoagulant medication, INR >1.3.
• Participants who cannot tolerate mild sedation.
• Participants with the following laboratory values, unless approved by hematologist: Platelet count <100,000/mL, Activated Partial Thromboplastin Time (APTT) >39 sec or Prothrombin Time (PT) >15 sec
• Pregnancy or lactation
• Patient is unable to comply with requirements of the procedure, i.e. holding breath
• Participation in an investigational trial within 30 days of enrollment.
• Any form of substance abuse (including drug or alcohol abuse), psychiatric disorder, or any chronic condition that could, in the opinion of the investigator, of interfering with the conduct of the study.
• Participants who are uncooperative or cannot follow instructions.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Perceptive Navigation LLC

UNKNOWN

Sponsor Role: collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

Sponsor Role: collaborator

Johns Hopkins University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Robert Liddell, MD

Role: PRINCIPAL_INVESTIGATOR

Johns Hopkins University

Locations

Johns Hopkins School of Medicine

Baltimore, Maryland, United States

Countries

United States

Other Identifiers

R42HL093879

Identifier Type: NIH

Identifier Source: secondary_id

View Link

R44HL093879

Identifier Type: NIH

Identifier Source: secondary_id

View Link

Z1822

Identifier Type: OTHER

Identifier Source: secondary_id

IRB00103043

Identifier Type: -

Identifier Source: org_study_id